-+ 0.00%
-+ 0.00%
-+ 0.00%

DESIGN THERAPEUTICS ANNOUNCES FOUR-WEEK IV DATA FROM THE RESTORE-FA TRIAL OF DT-216P2 DEMONSTRATING CLINICAL IMPROVEMENTS AND COMPREHENSIVE BIOMARKER ACTIVITY IN FRIEDREICH ATAXIA

Reuters·05/18/2026 11:00:02

Please log in to view news